Recombinant HEV Mosaic Protein

  • Check with publisher
  • Published date: February 25, 2019
    • Shirley, New York, United States

The hepatitis E virus (HEV), is the causative agent of hepatitis E. HEV is a small, non-enveloped, positive-sense single-stranded RNA virus with an icosahedral capsid. The global burden of infections from the two major genotypes (1 and 2) is estimated at 20 million per year, leading to 70,000 deaths and 3,000 stillbirths. HEV is the major cause of sporadic hepatitis, as well as epidemic hepatitis. Hepatitis E is an enterically transmitted infection that is typically self-limited. The HEV has a fecal-oral transmission route and can spread by the consumption of uncooked or undercooked meat or fecally contaminated water within endemic areas.
https://www.creative-biolabs.com/vaccine/recombinant-hev-mosaic-protein-270.htm

Result 0 votes
Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • 6th Annual Next Generation Sequencing USA Congress

    6th Annual Next Generation Sequencing USA Congress

    Life Sciences Boston (Massachusetts) November 28, 2019 Check with publisher

    350+ end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical & biotech companies. 3 outstanding programmes bringing together ...

  • 5th Annual Advances in Immuno-Oncology Congress

    5th Annual Advances in Immuno-Oncology Congress

    Life Sciences London (London) November 12, 2019 Check with publisher

    Over 350 attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and healthcare institutions developing immuno-oncology therapies and tools. Over 60 presentations, case studies and p...

  • 7th Annual Peptides & Oligonucleotides Congress

    7th Annual Peptides & Oligonucleotides Congress

    Life Sciences London (United Kingdom) November 6, 2019 Check with publisher

    Over 150 attendees working in peptides and oligonucleotides, representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions. Over 40 case studies, presentations and panel discussions foc...